Skip to main content
Premium Trial:

Request an Annual Quote

Takeda, Sage Bionetworks Partner to Find Drug Targets for CNS

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Takeda Pharmaceutical and Sage Bionetworks announced on Thursday a collaboration to identify drug targets for central nervous system diseases.

Under the agreement, Takeda, based in Osaka, Japan, will pay Sage $3.6 million in research funding and fees. Sage will develop a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS diseases.

The partners will then discover and prioritize the targets "that hold the greatest potential for molecular intervention," they said in a statement.

Further terms were not disclosed.

"We view this collaboration as an opportunity to further Takeda's goal of identifying targets for new therapeutics to treat the serious effects of CNS diseases where there is a high unmet need for patients all over the world," said Paul Chapman, general manager and head of the Pharmaceutical Research Division for Takeda.

Sage is a non-profit medical research organization based in Seattle that uses molecular and clinical datasets for improved therapeutic development.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.